These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 8018531)

  • 1. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
    Gurney H; Grill V; Martin TJ
    Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
    Body JJ; Dumon JC; Thirion M; Cleeren A
    J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
    Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
    J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
    Dodwell DJ; Abbas SK; Morton AR; Howell A
    Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Blind E; Raue F; Meinel T; Wüster C; Ziegler R
    Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):407-13. PubMed ID: 7955450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone related protein and hypercalcaemia in breast cancer.
    Bundred NJ; Ratcliffe WA; Walker RA; Coley S; Morrison JM; Ratcliffe JG
    BMJ; 1991 Dec; 303(6816):1506-9. PubMed ID: 1782489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy.
    Blind E; Raue F; Götzmann J; Schmidt-Gayk H; Kohl B; Ziegler R
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):290-7. PubMed ID: 1424212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone-related peptide, measured by a midmolecule radioimmunoassay, in various hypercalcaemic and normocalcaemic conditions.
    Bucht E; Eklund A; Toss G; Lewensohn R; Granberg B; Sjöstedt U; Eddeland R; Tørring O
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):294-300. PubMed ID: 1449040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome.
    Schweitzer DH; Hamdy NA; Frölich M; Zwinderman AH; Papapoulos SE
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):251-6. PubMed ID: 7923831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic significance of parathyroid hormone-related protein in tumor patients with hypercalcemia].
    Blind E; Raue F; Meinel T; Pecherstorfer M; Räth U; Schmidt-Gayk H; Kohl B; Ziegler R
    Dtsch Med Wochenschr; 1993 Mar; 118(10):330-5. PubMed ID: 8453901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.